Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Recent Advances and Perspectives in Cancer Drug Design

Author(s): Irena Kostova

Volume 29, Issue 22, 2023

Published on: 22 August, 2023

Page: [1711 - 1712] Pages: 2

DOI: 10.2174/138161282922230822111237

Next »
[1]
Moazamiyanfar R, Rezaei S, Ashrafzadeh HA, et al. Nobiletin in cancer therapy; mechanisms and therapy perspectives. Curr Pharm Des 2023; 29(22): 1713-28.
[2]
Katiyar S, Jin XH, Yadav D. Red Seaweed-derived compounds: A desired approach for treating cancer. Curr Pharm Des 2023; 29(22): 1729-40.
[3]
Hamilton G, Stickler S, Rath B. Targeting of SOS1: from SOS1 activators to proteolysis targeting chimeras. Curr Pharm Des 2023; 29(22): 1741-6.
[4]
Akitsu T, Tsvetkova D, Yamamoto Y, Nakane D, Kostova I. From basics of coordination chemistry to understanding cisplatin-analogue Pt drugs. Curr Pharm Des 2023; 29(22): 1747-74.
[5]
Ravuluri JAV, Rao V, Kumar G, et al. Brain-targeted nano-architectures for efficient drug delivery and sensitization in glioblastoma. Curr Pharm Des 2023; 29(22): 1775-90.
[6]
Serrano-Pindado A, Iorhemba MA, Díaz-García D, et al. Cytotoxic and DNA-binding capacity of titanocene functionalized mesoporous nanoparticles in breast cancer cell lines MCF-7 and MDA-MB-231. Curr Pharm Des 2023; 29(22): 1791-9.

© 2024 Bentham Science Publishers | Privacy Policy